Grail (company)
| Company type | Public |
|---|---|
| Nasdaq: GRAL | |
| Industry | Biotechnology |
| Founded | 2015 |
| Headquarters | , United States |
Key people |
|
| Products | Galleri test |
| Revenue | US$126 million (2024) |
| US$−2.2 billion (2024) | |
| US$−2.0 billion (2024) | |
| Total assets | US$2.98 billion (2024) |
| Total equity | US$2.50 billion (2024) |
Number of employees | 1,000 (2024) |
| Website | grail |
| Footnotes / references | |
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021 Galleri launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.